722 related articles for article (PubMed ID: 34448033)
1. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
[TBL] [Abstract][Full Text] [Related]
2. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
[TBL] [Abstract][Full Text] [Related]
3. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V
Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120
[TBL] [Abstract][Full Text] [Related]
4. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
Sen T; Li J; Neuen BL; Neal B; Arnott C; Parikh CR; Coca SG; Perkovic V; Mahaffey KW; Yavin Y; Rosenthal N; Hansen MK; Heerspink HJL
Diabetologia; 2021 Oct; 64(10):2147-2158. PubMed ID: 34415356
[TBL] [Abstract][Full Text] [Related]
5. Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
Weir MR; Gogate J; Damaraju CV; Correa-Rotter R; Mahaffey KW
Diabetes Obes Metab; 2022 Jan; 24(1):12-20. PubMed ID: 34463423
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data.
Zou X; Huang Q; Luo Y; Ren Q; Han X; Zhou X; Ji L
Diabetologia; 2022 Sep; 65(9):1424-1435. PubMed ID: 35802168
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
Yale JF; Xie J; Sherman SE; Garceau C
Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
[TBL] [Abstract][Full Text] [Related]
8. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
[TBL] [Abstract][Full Text] [Related]
9. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
[TBL] [Abstract][Full Text] [Related]
11. Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.
Wada T; Mori-Anai K; Kawaguchi Y; Katsumata H; Tsuda H; Iida M; Arakawa K; Jardine MJ
J Diabetes Investig; 2022 Jan; 13(1):54-64. PubMed ID: 34212533
[TBL] [Abstract][Full Text] [Related]
12. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
[TBL] [Abstract][Full Text] [Related]
14. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V;
J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Ways K; Desai M; Shaw W; Capuano G; Alba M; Jiang J; Vercruysse F; Meininger G; Matthews D;
Diabetes Care; 2015 Mar; 38(3):403-11. PubMed ID: 25468945
[TBL] [Abstract][Full Text] [Related]
16. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.
Sharma A; Razaghizad A; Joury A; Levin A; Bajaj HS; Mancini GBJ; Wong NC; Slee A; Ang FG; Rapattoni W; Neuen BL; Arnott C; Perkovic V; Mahaffey KW
J Am Heart Assoc; 2024 Feb; 13(3):e031586. PubMed ID: 38240199
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus.
Wilding JP; Blonde L; Leiter LA; Cerdas S; Tong C; Yee J; Meininger G
J Diabetes Complications; 2015 Apr; 29(3):438-44. PubMed ID: 25660137
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
[TBL] [Abstract][Full Text] [Related]
19. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Neal B; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Law G; Desai M; Matthews DR;
N Engl J Med; 2017 Aug; 377(7):644-657. PubMed ID: 28605608
[TBL] [Abstract][Full Text] [Related]
20. Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
Sridhar VS; Neuen BL; Fletcher RA; Slee A; Ang FG; Rapattoni W; Arnott C; Cherney DZ; Perkovic V; Wheeler DC; Levin A
Diabetes Obes Metab; 2023 Aug; 25(8):2331-2339. PubMed ID: 37184050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
